Date: 2 July, 2019 **Sydney, Australia**

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019

SYDNEY, 2 July, 2019: Noxopharm Ltd (ASX: NOX) ('Noxopharm' or the 'Company') is pleased to provide to the market the recording of the oral presentation given to the SNMMI 2019 Annual Meeting (Society of Nuclear Medicine and Molecular Imaging) by Associate Professor Louise Emmett, St Vincent's Hospital Sydney. NSW.

The recording can be found by visiting the Noxopharm website: www.noxopharm.com Recent Interviews

---

About Veyonda®

Veyonda® (previously known as NOX66) is a suppository dosage formulation of the experimental anti-cancer drug, idronoxil, that leads in the body to the formation of a proprietary pro-drug form. Idronoxil specifically inhibits the ability of cancer cells to respond to stress, such as that induced by radiation, leading to loss of pro-survival signaling via sphingosine-1-phosphate. Idronoxil also is a STING agonist, activating the body's innate immune system.

About ^{177}Lu-PSMA-617

PSMA-617 is a peptide targeting prostate membrane surface antigen, a protein expressed predominantly by prostate cancer cells. The peptide is linked to the radionuclide, ^{177}lutetium. The advantage of ^{177}Lu-PSMA-617 therapy is that following intravenous injection, it is able to reach prostate cancer cells throughout the body and to deliver radiotherapy (beta-radiation) in a highly targeted way. PSMA-617 is licensed to Endocyte Inc (a subsidiary of Novartis).

^{177}Lu-PSMA-617 therapy has been used in over 3,000 men to date on an experimental basis mainly in Germany and Australia. Endocyte (a subsidiary of Novartis) is conducting a Phase 3 registration study of ^{177}Lu-PSMA-617 in men with progressive mCRPC (VISION Study) in the U.S., Canada and Europe in approximately 750 men.

Standard use of ^{177}Lu-PSMA-617 is intravenous administration once weekly every six weeks for 30 weeks. The reported general outcome is that less than 50% of men complete the full course of 6 injections before suffering relapse.

About LuPIN

LuPIN is an Investigator-Initiated Phase Ib/IIa, single-arm, open label study enrolling 56 men with mCRPC that is progressing despite docetaxel, cabazitaxel and either abiraterone and/or enzalutamide. The study is divided into 4 cohorts of 400 mg (8 patients), 800 mg (8 patients), 800 mg (16 patients) and 1200 mg (24 patients) NOX66.

The Phase Ib arm of the study is intended to establish the safety of the combination treatment. The Phase IIa expansion arm is intended to establish the dose-response effect of increasing NOX66 levels on combination treatment safety and efficacy.

Imaging inclusion criteria include a PSMA PET/CT with uptake intensity in metastases more than twice the normal liver uptake and no discordant disease on FDG PET/CT. All men receive up to 6 doses of ^{177} Lu-PSMA 617 at 6-weekly intervals; the first 8 men received 400mg idronoxil (suppository) daily cycle days 1-10.

Following safety data review of the first cohort (400 mg NOX66), the dose for patients 9-16 was escalated to 800mg NOX66 daily. The study then was expanded to recruit a third cohort of 16 patients to receive 800 mg NOX66. With further evidence of efficacy and good tolerability, the study was expanded to include a fourth patient cohort (1200 mg NOX66).

About this data

This research was originally published in an earlier form in the Journal of Nuclear Medicine. *Emmett L et al. Interim results of a Phase I/II prospective dose escalation trial evaluation safety and efficacy of combination ^{177}Lu-PSMA-617 and NOX66 in men with mCRPC post androgen signaling inhibition and 2 lines of taxane chemotherapy (LuPIN trial).* The publication is available at the following link:
http://jnm.snmjournals.org/content/60/supplement_1/465.abstract?sid=77766228-dd3b-4ab5-b471-4dfa2257985c

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

www.noxopharm.com

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 9299 9690
E: David.Franks@automicgroup.com.au

Media Contact:
Cherilyn Cecchini, M.D.
LifeSci Public Relations
T: +1 646 876 5196
E: ccecchini@lifescipublicrelations.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.